Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide is a small molecule experimental compound with the molecular formula C16H14N2O3 and an average molecular weight of approximately 282.29 g/mol. It is known as an inhibitor of matrix metalloproteinase enzymes, specifically MMPs, which are involved in the breakdown of extracellular matrix components. This compound has been studied for its potential to inhibit MMP activity, which may be relevant in diseases involving tissue remodeling and degradation such as cancer metastasis or arthritis. However, it is not approved for clinical use and has no registered indications or marketed brand names. There are no known manufacturers or developers publicly listed for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-[(4'-cyanobiphenyl-4-yl)oxy]-N-hydroxypropanamide.